

25 November 2020

NSX Announcement

Postponement of Annual General Meeting

Sydney, Australia – The Board of Directors of The iQ Group Global Ltd (NSX:IQG) (the **Company**) has resolved to postpone its annual general meeting (**AGM**) scheduled for 27 November 2020 to 29 January 2021.

The postponement is consistent with the Company's constitution, which permits postponement of a general meeting (other than one requisitioned or called by shareholders in accordance with the *Corporations Act 2001* (Cth) and the regulations thereunder), upon a resolution of the Board of Directors. The postponement is also authorised under the 'no action' position adopted by the Australian Securities and Investments Commission in 20-113MR *ASIC to further extend financial reporting deadlines for listed and unlisted entities and amends 'no action' position for AGMs*.

"During the COVID period, The iQ Group Global group of companies has remained focussed on our objectives, seizing upon opportunities to accelerate our activities and advance medical innovation with life-changing impact," commented the Company's Chairman and Chief Executive Officer, Dr George Syrmalis. "The iQ Group Global's collaboration with Harvard's Wyss Institute to develop a COV-2 real time diagnostic test is one example.

"With The iQ Group Global actively pursuing a number of collaborations and partnerships in advanced stages, we look forward to being able to advise shareholders of definitive arrangements once ongoing negotiations have been finalised.

"Shareholders' attendance at, and participation in, our AGM is important to the Board. We welcome shareholders to join us at our rescheduled AGM in January 2021, which is currently proposed to be conducted in person, subject to all appropriate social distancing and COVID-safe precautions."

A revised Notice of Annual General Meeting will be published in advance of the rescheduled AGM.

This announcement has been authorised for release by the Company's Board of Directors.

Gerardo Incollingo Company Secretary

Tel: +61 2 9891 6044